From The Economic Times
Center-Right Owned by Bennett, Coleman & Co.Dr Reddy's bets on generic semaglutide, biosimilars
RSS excerpt
Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a…